GARS1
GARS1 (glycyl-tRNA synthetase 1, also known as GlyRS, GARS, CMT2D, DSMAV and SMAD1) is a class II aminoacyl-tRNA synthetase that attaches glycine to its cognate tRNA. It also produces the signalling molecule diadenosine tetraphosphate (Ap4A). Browse Assay Genie's current range of GARS1 research reagents below, or read on for the biology behind the target.
GARS1 catalyses the ATP-dependent ligation of glycine to the 3'-end of its cognate tRNA. The reaction proceeds through an aminoacyl-adenylate intermediate, Gly-AMP, and charged tRNA is then available for protein synthesis. In addition, the enzyme produces diadenosine tetraphosphate (Ap4A) by direct condensation of two ATP molecules. Ap4A is described as a universal pleiotropic signalling molecule needed for cell regulation pathways, and GARS1 may therefore play a special role in Ap4A homeostasis.
The GARS1 gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The enzyme is an (alpha)2 dimer and belongs to the class II family of tRNA synthetases, listed by HGNC in the group of class II aminoacyl tRNA synthetases. Two transcript variants encoding different isoforms have been reported. UniProt annotates the protein in several compartments: the cytoplasm, axons, the mitochondrion, and a secreted form including extracellular exosomes. This spread of locations makes localisation a useful consideration when designing experiments with a GARS1 antibody or GARS1 ELISA kit.
The gene's historical names reflect its disease associations: it was formerly listed as Charcot-Marie-Tooth neuropathy 2D, and the symbols CMT2D, DSMAV and SMAD1 remain in use as aliases. GARS1 has also been shown to be a target of autoantibodies in the human autoimmune diseases polymyositis and dermatomyositis. The mouse and rat orthologues are both named Gars1.
GARS1 charges tRNA with glycine via a Gly-AMP intermediate, making it a model for studying class II aminoacyl-tRNA synthetase catalysis.
The enzyme condenses two ATPs to form Ap4A, a pleiotropic signalling molecule, and may contribute to Ap4A homeostasis.
GARS1 carries the former name Charcot-Marie-Tooth neuropathy 2D and the aliases CMT2D and DSMAV, linking it to neuropathy research.
Glycyl-tRNA synthetase is a target of autoantibodies in polymyositis and dermatomyositis, making it relevant to autoimmunity studies.
GARS1 catalyses the ATP-dependent attachment of glycine to the 3'-end of its cognate tRNA through a Gly-AMP intermediate. It also makes diadenosine tetraphosphate (Ap4A) by condensing two ATPs, and may therefore help maintain Ap4A homeostasis.
GARS1 is also called glycyl-tRNA synthetase, glycine--tRNA ligase, GlyRS and GARS. Aliases CMT2D, DSMAV and SMAD1 reflect disease associations, and the earlier name was Charcot-Marie-Tooth neuropathy 2D. Two transcript variants encoding different isoforms have been described.
Mouse and rat both have a Gars1 orthologue, so rodent models can be used; check the datasheet of any product for its validated reactivity. In humans, GARS1 is a target of autoantibodies in polymyositis and dermatomyositis, and carries the former name CMT2D.
Other aminoacyl-tRNA synthetases and related translation and neuropathy targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P41250; product specifications from Assay Genie datasheets.